BioSpace News Archive

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (“LUMC”) for a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency (“RAG1-SCID”).

Hepion Pharmaceuticals, Inc. today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases

Eiger BioPharmaceuticals, Inc. today announced that David Cor , President and CEO, will provide a corporate update at two investor conference events in November:

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the third quarter of 2021 and provided an update on recent corporate activities.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:40 a.m. ET.

Boundless Bio today announced that Chief Business Officer, Neil Abdollahian, will present at the Stifel 2021 Virtual Healthcare Conference which will be webcast on Wednesday, November 17th, 2021, at 12:20 p.m. PST/3:20 p.m. EST.

Astria Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

A new randomized controlled clinical study finds that Hinge Health’s Enso delivers 2x more pain reduction and improves mobility 3x compared to a control device.